In a recent update on its pivotal Phase 3 clinical trial evaluating Lupuzor (rigerimod) as a potential treatment for lupus, ImmuPharma announced that it was complying with a request to open a trial site in Mauritius so that patients there could participate in the study. According to the company, the leading…
XTL Biopharmaceuticals announced that a patent has been issued covering the Europe Union for its leading drug candidate, hCDR1 (edratide), a potential treatment for systemic lupus erythematosus (SLE). The European Patent Office issue (EP1594434) is titled “Parenteral Formulations of Peptides for the Treatment of Systemic Lupus Erythematosus,” and covers formulations…
Maintaining optimal levels of vitamin D in the blood could be protective against the risk of cardiovascular disease often seen in systemic lupus erythematosus (SLE) patients, according to a large literature review conducted on the subject.
Lakeshore Recycling Systems (LRS) will join with the Lupus Society of Illinois (LSI) to raise money and disease awareness through the 2016 Chicago Illinois Lupus Walk. This year’s walk will take place on Sunday, Sept. 18, at Lincoln Park, from 9:00 a.m. to 1:00 p.m. Participants may choose distances of…
A recently released poll shows widespread public support among residents of San Jose, California, in favor of patient access to medical marijuana delivered to their homes — 63% in favor, in fact — as the City Council prepares to begin considering new regulations for businesses working in this area. Medical marijuana is…
Researchers at the Singapore Immunology Network at A*STAR have found that immune dendritic cells are crucial for the development of kidney disease in systemic lupus erythematosus (SLE). The study, “RNA sensing by conventional dendritic cells is central to the development of lupus nephritis,” was published in the journal…
Researchers found a specific class of adenosine receptors called A2A that works to counter the immune cell hyperactivation observed in systemic lupus erythematosus (SLE) patients, and may be a new target for disease treatment. The study, “A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus…
A recently published clinical study announced by Resolve Therapeutics shows that the levels of blood circulating RNA are connected to disease activity and immune stimulating gene expression in systemic lupus erythematosus (SLE) patients. The finding offers new treatment target for the disease. The study, “Blood-borne RNA correlates with disease activity and…
I’ve been wanting to talk about this subject for a while now, but it’s so complex a topic that I didn’t even know where to start. Hell, I hate ’em and love ’em all in the same instance, but they are a necessary evil in my life. You…
Anthera Pharmaceuticals announced that William Shanahan, MD, has been appointed its chief medical officer, with responsibilities that include advancing a potential treatment for systemic lupus erythematosus (SLE) now in a Phase 3 clinical study. Shanahan, a rheumatologist, brings to the company years of experience in drug development, and will lead the analysis of results…